{"id":"UC1_Q01","use_case":"UC1_fact_qa","question":"Selon les WFH Guidelines (3e édition), quels sont les composants clés d’un programme optimal de prise en charge de l’hémophilie ?","gold_sources":["paper"],"gold_files":["pdf-1865.pdf"],"gold_hints":["multidisciplinary","treatment centres","registry","procurement","distribution"]}
{"id":"UC1_Q02","use_case":"UC1_fact_qa","question":"Que recommandent les WFH Guidelines concernant l’existence d’un registre national des patients hémophiles ?","gold_sources":["paper"],"gold_files":["pdf-1865.pdf"],"gold_hints":["national registry","standardized data","centralized administration"]}
{"id":"UC1_Q03","use_case":"UC1_fact_qa","question":"Quel est le rôle d’un réseau de hemophilia treatment centres (HTCs) selon les WFH Guidelines ?","gold_sources":["paper"],"gold_files":["pdf-1865.pdf"],"gold_hints":["designated","treatment protocols","quality","audit"]}
{"id":"UC1_Q04","use_case":"UC1_fact_qa","question":"Dans le rapport canadien des standards de soins, combien de centres ont complété l’auto-évaluation ?","gold_sources":["paper"],"gold_files":["Comprehensive-care-standards-2022-2023-self-assessments.pdf"],"gold_hints":["26","treatment centres","self-assessments"]}
{"id":"UC1_Q05","use_case":"UC1_fact_qa","question":"Dans le rapport canadien, quel est le pourcentage global de standards respectés ?","gold_sources":["paper"],"gold_files":["Comprehensive-care-standards-2022-2023-self-assessments.pdf"],"gold_hints":["88.8%","standards"]}
{"id":"UC1_Q06","use_case":"UC1_fact_qa","question":"Dans l’étude rVWF prophylaxie VWD (US), combien de participants et combien de centres/sites ?","gold_sources":["paper"],"gold_files":["Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in th.pdf"],"gold_hints":["30","11 sites","retrospective chart review"]}
{"id":"UC1_Q07","use_case":"UC1_fact_qa","question":"Dans l’étude rVWF prophylaxie VWD, quelle proportion des participants reçoit une prophylaxie ‘routine’ ?","gold_sources":["paper"],"gold_files":["Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in th.pdf"],"gold_hints":["23","76.7%","routine prophylaxis"]}
{"id":"UC1_Q08","use_case":"UC1_fact_qa","question":"Quelle est la définition de la période baseline et de la période de traitement rVWF dans l’étude ?","gold_sources":["paper"],"gold_files":["Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in th.pdf"],"gold_hints":["1-year period before","1.5-year period following","baseline period"]}
{"id":"UC1_Q09","use_case":"UC1_fact_qa","question":"Dans l’étude rVWF prophylaxie VWD, de combien (en %) l’ABR global diminue-t-il pendant la période rVWF ?","gold_sources":["paper"],"gold_files":["Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in th.pdf"],"gold_hints":["ABR","decreased by 53%","ratio 0.47"]}
{"id":"UC1_Q10","use_case":"UC1_fact_qa","question":"Dans l’étude rVWF prophylaxie VWD, quels changements observe-t-on sur les major bleeds vs minor bleeds ?","gold_sources":["paper"],"gold_files":["Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in th.pdf"],"gold_hints":["major","-82%","minor","no observed difference"]}
{"id":"UC1_Q11","use_case":"UC1_fact_qa","question":"Combien de patients contient le registre (snapshot) fourni dans l’Excel (métrique total_patients) ?","gold_sources":["registry"],"gold_files":["registry_for_pipeline.xlsx"],"gold_hints":["total_patients"]}
{"id":"UC1_Q12","use_case":"UC1_fact_qa","question":"Quelle est la moyenne d’âge (mean_age_years) dans l’Excel de registre ?","gold_sources":["registry"],"gold_files":["registry_for_pipeline.xlsx"],"gold_hints":["mean_age_years"]}

{"id":"UC2_Q01","use_case":"UC2_struct_extraction","question":"Extrait (valeur numérique) : % de réduction ABR global (routine cohort) dans l’étude rVWF prophylaxie VWD.","gold_sources":["paper"],"gold_files":["Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in th.pdf"],"gold_hints":["53%","ABR","ratio"]}
{"id":"UC2_Q02","use_case":"UC2_struct_extraction","question":"Extrait : réduction (ou ratio) de major ABR dans l’étude rVWF prophylaxie VWD.","gold_sources":["paper"],"gold_files":["Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in th.pdf"],"gold_hints":["major bleeds","ratio 0.18","-82%"]}
{"id":"UC2_Q03","use_case":"UC2_struct_extraction","question":"Extrait : le nombre de standards (66) et les catégories principales citées dans le rapport canadien.","gold_sources":["paper"],"gold_files":["Comprehensive-care-standards-2022-2023-self-assessments.pdf"],"gold_hints":["66 standards","categories","information systems","audit","quality assurance"]}
{"id":"UC2_Q04","use_case":"UC2_struct_extraction","question":"Extrait : les domaines de pénurie de staffing mentionnés dans le rapport canadien (liste).","gold_sources":["paper"],"gold_files":["Comprehensive-care-standards-2022-2023-self-assessments.pdf"],"gold_hints":["physiotherapy","social work","data entry","data management"]}
{"id":"UC2_Q05","use_case":"UC2_struct_extraction","question":"Extrait : les 3 composants ‘registry / governance’ cités dans les WFH Guidelines (registre, privacy/consent, audit/quality).","gold_sources":["paper"],"gold_files":["pdf-1865.pdf"],"gold_hints":["privacy","confidentiality","consent","audit","quality"]}
{"id":"UC2_Q06","use_case":"UC2_struct_extraction","question":"Extrait (Excel) : proportion hemophilia A vs B (metrics hemophilia_a_proportion, hemophilia_b_proportion).","gold_sources":["registry"],"gold_files":["registry_for_pipeline.xlsx"],"gold_hints":["hemophilia_a_proportion","hemophilia_b_proportion"]}
{"id":"UC2_Q07","use_case":"UC2_struct_extraction","question":"Extrait (Excel) : proportion severe vs moderate vs mild.","gold_sources":["registry"],"gold_files":["registry_for_pipeline.xlsx"],"gold_hints":["severe_proportion","moderate_proportion","mild_proportion"]}
{"id":"UC2_Q08","use_case":"UC2_struct_extraction","question":"Extrait (Excel) : median factor VIII level (%) et median factor IX level (%).","gold_sources":["registry"],"gold_files":["registry_for_pipeline.xlsx"],"gold_hints":["median_factor_viii_level","median_factor_ix_level"]}
{"id":"UC2_Q09","use_case":"UC2_struct_extraction","question":"Extrait (Excel) : mean bleeds last 12 months.","gold_sources":["registry"],"gold_files":["registry_for_pipeline.xlsx"],"gold_hints":["mean_bleeds_last_12m"]}
{"id":"UC2_Q10","use_case":"UC2_struct_extraction","question":"Extrait (Excel) : proportion sous prophylaxie vs à la demande.","gold_sources":["registry"],"gold_files":["registry_for_pipeline.xlsx"],"gold_hints":["prophylaxis_proportion","on_demand_proportion"]}
{"id":"UC2_Q11","use_case":"UC2_struct_extraction","question":"Extrait (Excel) : inhibitor prevalence et median inhibitor titer.","gold_sources":["registry"],"gold_files":["registry_for_pipeline.xlsx"],"gold_hints":["inhibitor_prevalence","median_inhibitor_titer"]}
{"id":"UC2_Q12","use_case":"UC2_struct_extraction","question":"Extrait : dans l’étude rVWF, les types majeurs de VWD (Type 1/2/3) sont décrits comment ?","gold_sources":["paper"],"gold_files":["Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in th.pdf"],"gold_hints":["Type 1","Type 2","Type 3","qualitative","quantitative"]}

{"id":"UC3_Q01","use_case":"UC3_protocol_draft","question":"Rédige un brouillon structuré de section ‘Organisation des soins’ pour hémophilie (Tunisie), en t’appuyant sur les WFH Guidelines (réseau de centres + registre). Citations obligatoires.","gold_sources":["paper"],"gold_files":["pdf-1865.pdf"],"gold_hints":["treatment centres","registry","audit","protocols"]}
{"id":"UC3_Q02","use_case":"UC3_protocol_draft","question":"Rédige un brouillon de section ‘Suivi / monitoring’ pour une prophylaxie VWD par rVWF (haut niveau), en mentionnant limites + incertitudes. Citations obligatoires.","gold_sources":["paper"],"gold_files":["Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in th.pdf"],"gold_hints":["ABR","HCRU","limitations","sample size"]}
{"id":"UC3_Q03","use_case":"UC3_protocol_draft","question":"Rédige un paragraphe ‘Country notes (Tunisie)’ basé sur le registre : taille cohorte, sévérité dominante, part prophylaxie. Citations obligatoires vers l’Excel (chunks registry).","gold_sources":["registry"],"gold_files":["registry_for_pipeline.xlsx"],"gold_hints":["total_patients","severe_proportion","prophylaxis_proportion"]}
{"id":"UC3_Q04","use_case":"UC3_protocol_draft","question":"Produis une section ‘Adverse events / complications’ (niveau prudent) en te limitant aux évidences présentes dans le corpus. Si insuffisant: UNSUPPORTED + ce qui manque.","gold_sources":["paper","registry"],"gold_files":["pdf-1865.pdf","registry_for_pipeline.xlsx"],"gold_hints":["adverse","inhibitor","complications"]}
{"id":"UC3_Q05","use_case":"UC3_protocol_draft","question":"Pour une question large : ‘Quelle stratégie de réduction des bleeds est supportée dans la VWD sévère ?’ Donne réponse courte + citations, sinon dis ce qui manque.","gold_sources":["paper"],"gold_files":["Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in th.pdf"],"gold_hints":["prophylaxis","reduced ABR"]}
{"id":"UC3_Q06","use_case":"UC3_protocol_draft","question":"Synthèse: propose une structure de protocole (rubriques) pour troubles de l’hémostase, en justifiant la partie ‘registre’ (auditabilité) vs ‘littérature’. Citations obligatoires.","gold_sources":["paper"],"gold_files":["pdf-1865.pdf","Comprehensive-care-standards-2022-2023-self-assessments.pdf"],"gold_hints":["registry","audit","standards"]}
